These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 11675364)

  • 1. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report.
    Piekarz RL; Robey R; Sandor V; Bakke S; Wilson WH; Dahmoush L; Kingma DM; Turner ML; Altemus R; Bates SE
    Blood; 2001 Nov; 98(9):2865-8. PubMed ID: 11675364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
    Sandor V; Bakke S; Robey RW; Kang MH; Blagosklonny MV; Bender J; Brooks R; Piekarz RL; Tucker E; Figg WD; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; Bates SE
    Clin Cancer Res; 2002 Mar; 8(3):718-28. PubMed ID: 11895901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells.
    Shaker S; Bernstein M; Momparler LF; Momparler RL
    Leuk Res; 2003 May; 27(5):437-44. PubMed ID: 12620295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells.
    Kitazono M; Robey R; Zhan Z; Sarlis NJ; Skarulis MC; Aikou T; Bates S; Fojo T
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3430-5. PubMed ID: 11443220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.
    Nakajima H; Kim YB; Terano H; Yoshida M; Horinouchi S
    Exp Cell Res; 1998 May; 241(1):126-33. PubMed ID: 9633520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.
    Piekarz RL; Frye R; Prince HM; Kirschbaum MH; Zain J; Allen SL; Jaffe ES; Ling A; Turner M; Peer CJ; Figg WD; Steinberg SM; Smith S; Joske D; Lewis I; Hutchins L; Craig M; Fojo AT; Wright JJ; Bates SE
    Blood; 2011 Jun; 117(22):5827-34. PubMed ID: 21355097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
    Shimony S; Horowitz N; Ribakovsky E; Rozovski U; Avigdor A; Zloto K; Berger T; Avivi I; Perry C; Abadi U; Raanani P; Gafter-Gvili A; Gurion R
    Hematol Oncol; 2019 Dec; 37(5):569-577. PubMed ID: 31674027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.
    Klisovic MI; Maghraby EA; Parthun MR; Guimond M; Sklenar AR; Whitman SP; Chan KK; Murphy T; Anon J; Archer KJ; Rush LJ; Plass C; Grever MR; Byrd JC; Marcucci G
    Leukemia; 2003 Feb; 17(2):350-8. PubMed ID: 12592335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo.
    Sasakawa Y; Naoe Y; Inoue T; Sasakawa T; Matsuo M; Manda T; Mutoh S
    Biochem Pharmacol; 2002 Oct; 64(7):1079-90. PubMed ID: 12234611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.
    Aron JL; Parthun MR; Marcucci G; Kitada S; Mone AP; Davis ME; Shen T; Murphy T; Wickham J; Kanakry C; Lucas DM; Reed JC; Grever MR; Byrd JC
    Blood; 2003 Jul; 102(2):652-8. PubMed ID: 12649137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells.
    Sato N; Ohta T; Kitagawa H; Kayahara M; Ninomiya I; Fushida S; Fujimura T; Nishimura G; Shimizu K; Miwa K
    Int J Oncol; 2004 Mar; 24(3):679-85. PubMed ID: 14767553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells.
    Kitazono M; Rao VK; Robey R; Aikou T; Bates S; Fojo T; Goldsmith ME
    Blood; 2002 Mar; 99(6):2248-51. PubMed ID: 11877306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
    Kato Y; Egusa C; Maeda T; Tsuboi R
    J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma.
    Bates SE; Zhan Z; Steadman K; Obrzut T; Luchenko V; Frye R; Robey RW; Turner M; Gardner ER; Figg WD; Steinberg SM; Ling A; Fojo T; To KW; Piekarz RL
    Br J Haematol; 2010 Jan; 148(2):256-67. PubMed ID: 19874311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity.
    Blagosklonny MV; Robey R; Sackett DL; Du L; Traganos F; Darzynkiewicz Z; Fojo T; Bates SE
    Mol Cancer Ther; 2002 Sep; 1(11):937-41. PubMed ID: 12481415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCR 20th Anniversary Commentary: Expanding the Epigenetic Therapeutic Portfolio.
    Bates SE; Robey RW; Piekarz RL
    Clin Cancer Res; 2015 May; 21(10):2195-7. PubMed ID: 25979924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins.
    Blanchard F; Kinzie E; Wang Y; Duplomb L; Godard A; Held WA; Asch BB; Baumann H
    Oncogene; 2002 Sep; 21(41):6264-77. PubMed ID: 12214267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitors: novel agents in cancer treatment.
    Glass E; Viale PH
    Clin J Oncol Nurs; 2013 Feb; 17(1):34-40. PubMed ID: 23372094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
    Piekarz RL; Frye R; Turner M; Wright JJ; Allen SL; Kirschbaum MH; Zain J; Prince HM; Leonard JP; Geskin LJ; Reeder C; Joske D; Figg WD; Gardner ER; Steinberg SM; Jaffe ES; Stetler-Stevenson M; Lade S; Fojo AT; Bates SE
    J Clin Oncol; 2009 Nov; 27(32):5410-7. PubMed ID: 19826128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptosis induced by the histone deacetylase inhibitor FR901228 in human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells.
    Mori N; Matsuda T; Tadano M; Kinjo T; Yamada Y; Tsukasaki K; Ikeda S; Yamasaki Y; Tanaka Y; Ohta T; Iwamasa T; Tomonaga M; Yamamoto N
    J Virol; 2004 May; 78(9):4582-90. PubMed ID: 15078940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.